
pmid: 17129727
Limb girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi Myopathy are caused by mutations in the dysferlin gene. The phenotype of these allelic disease variants can vary considerably. We report on an adolescent female with a severe and rapidly progressing clinical course of LGMD2B which has been suggested by the muscle histopathology and Western blot and proven by mutation analysis in the Dysferlin gene. We detected a novel compound heterozygous mutation of which one affects the extracellular part of the protein. This is the first report on a mutation in this region of dysferlin and might explain the unusual phenotype of the patient.
Heterozygote, Leg, Adolescent, Blotting, Western, Muscle Fibers, Skeletal, Membrane Proteins, Muscle Proteins, DNA, Hypertrophy, Immunohistochemistry, Phenotype, Muscular Dystrophies, Limb-Girdle, Codon, Nonsense, Humans, Electrophoresis, Polyacrylamide Gel, Female, Muscle, Skeletal, Dysferlin
Heterozygote, Leg, Adolescent, Blotting, Western, Muscle Fibers, Skeletal, Membrane Proteins, Muscle Proteins, DNA, Hypertrophy, Immunohistochemistry, Phenotype, Muscular Dystrophies, Limb-Girdle, Codon, Nonsense, Humans, Electrophoresis, Polyacrylamide Gel, Female, Muscle, Skeletal, Dysferlin
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 22 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
